格拉司琼（BRL 43694）用于治疗细胞毒性药物引起的呕吐：综述 - Suppr

Suppr

超能文献

Granisetron (BRL 43694) in the treatment of cytostatic drug-induced emesis: a summary.

作者信息

Pintens H

机构信息

Beecham Pharmaceuticals, European Division, Brussels, Belgium.

出版信息

Cancer Treat Rev. 1990 Sep;17(2-3):307-10. doi: 10.1016/0305-7372(90)90062-k.

DOI:10.1016/0305-7372(90)90062-k

PMID:2176932

Abstract

摘要

相似文献

Granisetron (BRL 43694) in the treatment of cytostatic drug-induced emesis: a summary.格拉司琼（BRL 43694）用于治疗细胞毒性药物引起的呕吐：综述

Cancer Treat Rev. 1990 Sep;17(2-3):307-10. doi: 10.1016/0305-7372(90)90062-k.

Antiemetic control: 5-HT3 antagonists: review of clinical results, with particular emphasis on ondansetron.止吐控制：5-羟色胺3拮抗剂：临床结果综述，尤其侧重于昂丹司琼。

Cancer Treat Rev. 1990 Sep;17(2-3):311-7. doi: 10.1016/0305-7372(90)90063-l.

Repeated use of granisetron in patients receiving cytostatic agents.

Cancer. 1993 Jun 15;71(12):4043-9. doi: 10.1002/1097-0142(19930615)71:12<4043::aid-cncr2820711239>3.0.co;2-a.

The symptomatic control of cytostatic drug-induced emesis. A recent history and review.细胞毒性药物所致呕吐的症状控制。近期病史及综述。

Eur J Cancer. 1990;26 Suppl 1:S2-8.

Clinical studies with granisetron, a new 5-HT3 receptor antagonist for the treatment of cancer chemotherapy-induced emesis. The Granisetron Study Group.使用格拉司琼（一种用于治疗癌症化疗引起呕吐的新型5-羟色胺3受体拮抗剂）的临床研究。格拉司琼研究小组。

Eur J Cancer. 1993;29A Suppl 1:S22-9. doi: 10.1016/s0959-8049(05)80256-4.

RG 12915: a potent 5-hydroxytryptamine-3 antagonist that is an orally effective inhibitor of cytotoxic drug-induced emesis in the ferret and dog.RG 12915：一种强效的5-羟色胺-3拮抗剂，是雪貂和犬中细胞毒性药物诱发呕吐的口服有效抑制剂。

J Pharmacol Exp Ther. 1990 Aug;254(2):450-5.

[BRL 43694A--a 5-hydroxytryptamine receptor blocker as an antiemetic in cytostatic therapy].[BRL 43694A——一种5-羟色胺受体阻滞剂，作为细胞抑制疗法中的止吐药]

Schweiz Med Wochenschr. 1989 Jun 10;119(23):831-4.

Superiority of granisetron to dexamethasone plus prochlorperazine in the prevention of chemotherapy-induced emesis.格拉司琼在预防化疗引起的呕吐方面优于地塞米松加异丙嗪。

J Natl Cancer Inst. 1991 Aug 21;83(16):1169-73. doi: 10.1093/jnci/83.16.1169.

A phase I study of a new 5HT3-receptor antagonist, BRL43694A, an agent for the prevention of chemotherapy-induced nausea and vomiting.新型5HT3受体拮抗剂BRL43694A预防化疗引起的恶心和呕吐的I期研究。

Cancer Chemother Pharmacol. 1989;24(3):193-6. doi: 10.1007/BF00300242.

[Chemotherapy-induced emesis and serotonin antagonists].

Duodecim. 1991;107(14):1112-5.

引用本文的文献

Benefits and risks of newer treatments for chemotherapy-induced and postoperative nausea and vomiting.新型化疗诱导性和术后恶心呕吐治疗方法的益处与风险

Drug Saf. 2003;26(4):227-59. doi: 10.2165/00002018-200326040-00003.

Volunteer models for predicting antiemetic activity of 5-HT3-receptor antagonists.用于预测5-羟色胺3受体拮抗剂止吐活性的志愿者模型。

Br J Clin Pharmacol. 1994 Jun;37(6):525-30. doi: 10.1111/j.1365-2125.1994.tb04298.x.

Adjuvant propofol enables better control of nausea and emesis secondary to chemotherapy for breast cancer.辅助使用丙泊酚能更好地控制乳腺癌化疗引起的恶心和呕吐。

Can J Anaesth. 1994 Nov;41(11):1117-9. doi: 10.1007/BF03015664.

Granisetron. A review of its pharmacological properties and therapeutic use as an antiemetic.格拉司琼。其药理特性及作为止吐药的治疗用途综述。

Drugs. 1991 Nov;42(5):805-24. doi: 10.2165/00003495-199142050-00007.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验